Your browser is no longer supported. Please, upgrade your browser.
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Stats
Total: 104 #1
CompanyConstellation Pharmaceuticals, Inc.
Market Cap372.79MEPS (ttm)-2.95
P/E-EPS this Y-16.80%
Forward P/E-EPS next Y-1.00%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B5.68EPS Q/Q-82.20%
Dividend-Sales Q/Q-
Insider Own0.30%Inst Own81.80%
Insider Trans-Inst Trans0.21%
Short Float2.49%EarningsNov 14/b
Analyst Recom1.60Target Price17.29
Avg Volume122.15K52W Range4.01 - 15.63
Nov-06-19 09:00AMConstellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial Results GlobeNewswire
Oct-31-19 10:00AMHere's Why Momentum Investors Will Love Constellation Pharmaceuticals, Inc. (CNST) Zacks
Oct-14-19 08:06AMWill Constellation Pharmaceuticals Continue to Surge Higher? Zacks
Oct-10-19 07:00AMConstellation Pharmaceuticals Announces MANIFEST Data Updates Will Be Provided in Oral and Poster Sessions on December 9 at ASH GlobeNewswire
Oct-04-19 08:52AMConstellation Pharmaceuticals (CNST) Looks Good: Stock Adds 8.3% in Session Zacks
Oct-01-19 07:00AMConstellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors GlobeNewswire
Sep-26-19 12:00PMConstellation Pharmaceuticals to Present at Cantor Global Healthcare Conference GlobeNewswire
Sep-24-19 07:00AMConstellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise GlobeNewswire
Sep-23-19 07:17PMInvestors May Want to Follow the Progress of These Biotechs
Aug-21-19 09:00AMConstellation Pharmaceuticals to Participate in Two Investor Conferences GlobeNewswire
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
CompanyASLAN Pharmaceuticals Limited
Market Cap56.41MEPS (ttm)-0.86
P/E-EPS this Y54.30%
Forward P/E-EPS next Y7.80%
PEG-EPS past 5Y-
P/S18.80EPS next 5Y-
P/B4.29EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own9.35%
Insider Trans-Inst Trans-
Short Float0.11%EarningsAug 12
Analyst Recom-Target Price7.75
Avg Volume19.83K52W Range1.46 - 6.48
Oct-31-19 03:37AMASLAN Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Oct-22-19 02:45AMASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis GlobeNewswire
Oct-18-19 03:35AMASLAN Pharmaceuticals Announces Closing of US$3 Million Loan Facility GlobeNewswire
Oct-02-19 02:30AMNew Data Presented on ASLANs varlitinib at ESMO 2019 GlobeNewswire
Sep-30-19 02:35AMASLAN Pharmaceuticals and Bukwang Pharmaceutical Establish a Joint Venture, JAGUAHR Therapeutics, to Develop Novel Immuno-Oncology Therapies GlobeNewswire
Sep-19-19 03:50AMASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO GlobeNewswire
Sep-10-19 05:14AMAbstract on ASLAN Pharmaceuticals Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019 GlobeNewswire
Aug-27-19 06:00AMNew Data From Aslans Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting GlobeNewswire
Aug-13-19 04:03AMASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-31-19 04:14AMASLAN Pharmaceuticals to Present New Data on Varlitinib at European Society for Medical Oncology Congress GlobeNewswire
ASLAN Pharmaceuticals Limited operates as a clinical-stage oncology and inflammatory disease focused biopharmaceutical company in the United States. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor (HER), inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4, as well as gastric cancer. Its Varlitinib is currently being studied in a pivotal clinical trial for biliary tract cancer. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. Further, it develops ASLAN005, an antibody that is in preclinical development targeting recepteur d'origine nantais, an immune checkpoint inhibitor. The company has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has licensing agreement with Array BioPharma, Bristol-Myers Squibb, Almirall, CSL Limited, Hyundai Pharm Co., Ltd., Exploit Technologies Pte Ltd., and BioGenetics Co. Ltd.; and licensing and research collaboration agreement with Nanyang Technological University. The company was founded in 2010 and is headquartered in Singapore.
CompanycomScore, Inc.
IndustryBusiness Services
Market Cap153.26MEPS (ttm)-5.94
P/E-EPS this Y45.20%
Forward P/E-EPS next Y80.20%
PEG-EPS past 5Y-57.21%
P/S0.37EPS next 5Y20.00%
P/B0.56EPS Q/Q-354.10%
Dividend-Sales Q/Q-4.40%
Insider Own0.40%Inst Own74.40%
Insider Trans-Inst Trans3.82%
Short Float8.93%EarningsNov 05/a
Analyst Recom2.60Target Price4.90
Avg Volume927.50K52W Range1.43 - 23.89
Nov-05-19 07:55PMComScore (SCOR) Reports Q3 Loss, Misses Revenue Estimates Zacks
Nov-05-19 04:37PMComscore Reports Third Quarter 2019 Results and Announces Leadership Transition PR Newswire
Oct-28-19 04:01PMComscore Sets Date to Announce Third Quarter 2019 Financial Results PR Newswire
Oct-28-19 10:30AMDiscovery, Inc. and Comscore Announce Broad Strategic Partnership Across Measurement, Targeting and Segmentation PR Newswire
Oct-28-19 10:15AMComscore Signs Multi-Year Deal with Cinemex to Provide Industry Leading Data Analytics Platform PR Newswire
Oct-21-19 10:30AMComscore Announces Agreement with Premion to Provide Measurement for Leading CTV/OTT Platform PR Newswire
Oct-15-19 09:00AMComscore Introduces Next Generation Theatre Management System: Cinema Auditorium Control Engine PR Newswire
Oct-04-19 05:00AMComScore might have only one card left to play American City Business Journals
Oct-03-19 08:00AMComscore Partners with Media Solutions Pioneer CTV Media to Deliver Television Audience Measurement PR Newswire
Oct-01-19 08:15AMLocal Broadcast Pioneer Sarkes Tarzian Inc. Expands Relationship with Comscore Across their Full Station Group PR Newswire
comScore, Inc. operates as an information and analytics company that measures audiences, consumer behavior, and advertising across media platforms worldwide. The company offers ratings and planning products and services, including Media Metrix and Mobile Metrix, which measure Websites and apps on computers, smartphones, and tablets; Video Metrix that delivers unduplicated measurement of digital video consumption, as well as provides TV-comparable reach and engagement metrics, and audience demographics; Plan Metrix, which offers an understanding of consumer lifestyle; validated Campaign Essentials (vCE) that validates whether digital ad impressions are visible to humans, identifies those that are fraudulent, and verifies that ads are shown in brand safe content and delivered to the right audience targets; and Campaign Ratings, which expands upon vCE's verification, as well as provides unduplicated reporting to negotiate and evaluate campaigns across media platforms. Its ratings and planning products and services also comprises TV Essentials that combines TV viewing information with marketing segmentation and consumer databases; StationView Essentials to understand consumer viewing patterns and characteristics; OnDemand Essentials that provides transactional tracking and reporting; and Cross-Platform Suite, which integrates person-level linear TV viewership with digital audience data. The company also offers analytics and optimization products and services that provide end-to-end solutions for planning, optimization, and evaluation of advertising campaigns and brand protection. In addition, it offers movies reporting and analytics products and services to measure movie viewership and box office results by capturing movie ticket sales in real time or near real time, which include box office analytics, trend analysis, and insights for movie studios and movie theater operators. The company was founded in 1999 and is headquartered in Reston, Virginia.
CompanyVenator Materials PLC
CountryUnited Kingdom
IndustrySpecialty Chemicals
Market Cap289.92MEPS (ttm)-3.94
P/E-EPS this Y-226.70%
Forward P/E4.51EPS next Y89.21%
PEG-EPS past 5Y-
P/S0.13EPS next 5Y-
P/B0.36EPS Q/Q-89.30%
Dividend-Sales Q/Q-7.70%
Insider Own0.30%Inst Own45.40%
Insider Trans-Inst Trans0.14%
Short Float3.32%EarningsNov 06/b
Analyst Recom2.30Target Price5.21
Avg Volume503.27K52W Range1.85 - 7.24
Nov-06-19 07:35AMVentator Materials (VNTR) Surpasses Q3 Earnings and Revenue Estimates Zacks
Nov-06-19 06:00AMVenator Announces Third Quarter 2019 Results; Stable Sequential TiO2 Pricing and Accelerated Delivery of Cost Initiatives PR Newswire
Oct-30-19 10:33AMAnalysts Estimate Ventator Materials (VNTR) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-08-19 04:30PMVenator to Discuss Third Quarter 2019 Results on November 6, 2019 PR Newswire
Sep-27-19 10:30AMCLASS ACTION UPDATE for VNTR, GTT and CURLF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
Sep-27-19 09:41AMDEADLINE ALERT - Venator Materials PLC (VNTR) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Deadline: September 30, 2019 ACCESSWIRE
Sep-26-19 04:51PMSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Venator Materials PLC of Class Action Lawsuit and Upcoming Deadline - VNTR PR Newswire
Sep-26-19 03:30PMThe Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VNTR, NTAP and TXT ACCESSWIRE
Sep-26-19 03:00PMINVESTOR ALERT - Venator Materials PLC (VNTR) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Deadline: September 30, 2019 GlobeNewswire
Sep-26-19 12:10PMFILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of VNTR, MGNX and DXC ACCESSWIRE
Venator Materials PLC manufactures and markets chemical products worldwide. It operates through two segments, Titanium Dioxide and Performance Additives. The Titanium Dioxide segment offers titanium dioxide (TiO2), such as rutile, anatase, and nano TiO2 products for use in coatings, plastics, paper, printing inks, fibers, and food and personal care products. The Performance Additives segment provides barium and zinc additives for use in coatings, films, pharmaceuticals, and paper and glass fiber reinforced plastics; colored inorganic pigments comprising iron oxides, ultramarines, specialty inorganics chemicals, and driers for construction, coating, plastic, and specialty markets; and wood protection chemicals for use in residential and commercial applications, as well as water treatment chemicals. The company was founded in 2017 and is headquartered in Stockton-On-Tees, the United Kingdom.
CompanyInogen, Inc.
IndustryMedical Instruments & Supplies
Market Cap1.29BEPS (ttm)1.87
P/E31.79EPS this Y76.40%
Forward P/E46.38EPS next Y17.99%
PEG2.88EPS past 5Y187.70%
P/S3.47EPS next 5Y11.05%
P/B3.88EPS Q/Q-30.00%
Dividend-Sales Q/Q4.00%
Insider Own0.90%Inst Own-
Insider Trans1.55%Inst Trans-0.94%
Short Float13.96%EarningsNov 05/a
Analyst Recom2.70Target Price53.75
Avg Volume551.77K52W Range41.19 - 197.80
Nov-06-19Upgrade Needham Hold → Buy $90
Nov-06-19 09:13AMInogen's (INGN) Q3 Earnings and Revenues Beat Estimates Zacks
Nov-05-19 07:05PMInogen (INGN) Q3 Earnings and Revenues Top Estimates Zacks
Nov-05-19 04:05PMInogen Announces Third Quarter 2019 Financial Results Business Wire
Oct-29-19 10:33AMAnalysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-28-19 09:03AMInogen Inc (INGN): Hedge Funds Turning Bullish, But Not Bullish Enough Insider Monkey
Oct-25-19 11:10AMIs Inogen, Inc.'s (NASDAQ:INGN) CEO Overpaid Relative To Its Peers? Simply Wall St.
Oct-22-19 04:05PMInogen to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019 Business Wire
Oct-11-19 01:21PMShareholder Alert: Robbins Arroyo LLP Reminds Investors Inogen, Inc. (INGN) Sued for Misleading Shareholders Business Wire
Oct-08-19 08:40PMBragar Eagel & Squire, P.C. Is Investigating Certain Officers and Directors of Inogen, Inc. (NASDAQ: INGN) and Encourages Inogen Investors to Contact the Firm Business Wire
Oct-07-19 02:38PMIs Inogen's (NASDAQ:INGN) 124% Share Price Increase Well Justified? Simply Wall St.
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McFarland Loren LDirectorSep 04Buy42.931,00042,9314,481Sep 05 05:38 PM
Bauerlein AlisonEVP, Finance, & CFOAug 23Option Exercise9.934,00039,73933,224Aug 27 06:18 PM
Lukatch HeathDirectorAug 15Buy43.012,00086,0205,481Aug 19 08:11 PM
Huggenberger RaymondDirectorJan 15Option Exercise31.188,500264,99516,297Jan 16 05:30 PM
Huggenberger RaymondDirectorJan 15Sale136.818,5001,162,9177,797Jan 16 05:30 PM
CompanyBoingo Wireless, Inc.
IndustryDiversified Communication Services
Market Cap436.60MEPS (ttm)-0.12
P/E-EPS this Y94.80%
Forward P/E-EPS next Y25.80%
PEG-EPS past 5Y23.60%
P/S1.63EPS next 5Y-
P/B4.53EPS Q/Q-89.60%
Dividend-Sales Q/Q15.10%
Insider Own4.00%Inst Own95.60%
Insider Trans-6.19%Inst Trans0.31%
Short Float11.38%EarningsNov 05/a
Analyst Recom1.60Target Price26.69
Avg Volume705.10K52W Range8.85 - 26.67
Nov-06-19Reiterated Craig Hallum Buy $22 → $18
Nov-06-19 02:08AMEdited Transcript of WIFI earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-05-19 06:05PMBoingo Wireless (WIFI) Reports Break-Even Earnings for Q3 Zacks
Nov-05-19 04:01PMBoingo Wireless Reports Third Quarter 2019 Financial Results Business Wire
Nov-05-19 07:52AMIIROC Trading Halt - WIFI CNW Group
Oct-31-19 09:10AMIs Boingo Wireless (WIFI) Stock Undervalued Right Now? Zacks
Oct-30-19 09:10AMShould Value Investors Buy Boingo Wireless (WIFI) Stock? Zacks
Oct-29-19 10:33AMAnalysts Estimate Boingo Wireless (WIFI) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-25-19 01:37PMBoingo Wireless (NASDAQ:WIFI) Is Making Moderate Use Of Debt Simply Wall St.
Oct-22-19 09:00AMBoingo Wireless to Report Third Quarter 2019 Financial Results on Tuesday, November 5th Business Wire
Oct-16-19 09:00AMBoingo to Showcase LTE and Wi-Fi 6 Network with Converged Virtualized Core at Mobile World Congress Los Angeles Business Wire
Boingo Wireless, Inc., together with its subsidiaries, provides wireless connectivity solutions for smartphones, tablets, laptops, wearables, and other wireless-enabled consumer devices worldwide. The company offers distributed antenna systems and small cell networks at managed and operated locations; high-speed Wi-Fi services for residential consumers on military bases and at multifamily properties; and wholesale Wi-Fi services to network operators, device manufacturers, technology companies, enterprise software and services companies, venue operators, and financial services companies, as well as retail Internet access services. It serves largest carriers, telecommunications service providers, global consumer brands, and property owners, as well as troops stationed at military bases and Internet savvy consumers. The company was formerly known as Project Mammoth, Inc. and changed its name to Boingo Wireless, Inc. in October 2001. Boingo Wireless, Inc. was founded in 2001 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Peterson DerekChief Technology OfficerNov 01Option Exercise0.004,569051,639Nov 05 05:06 PM
Callahan DawnChief Marketing OfficerNov 01Option Exercise0.003,542018,901Nov 05 05:05 PM
Davis ChuckDirectorOct 11Option Exercise8.0136,000288,24095,887Oct 15 04:32 PM
Peterson DerekChief Technology OfficerSep 12Sale14.0210,715150,22448,911Sep 16 04:12 PM
Finley MichaelChief Executive OfficerAug 15Buy11.0010,000110,00061,873Aug 15 04:24 PM
CompanyTrupanion, Inc.
IndustryAccident & Health Insurance
Market Cap834.67MEPS (ttm)-0.07
P/E-EPS this Y59.20%
Forward P/E8013.33EPS next Y100.00%
PEG-EPS past 5Y37.70%
P/S2.45EPS next 5Y15.00%
P/B6.34EPS Q/Q-354.70%
Dividend-Sales Q/Q25.60%
Insider Own5.90%Inst Own-
Insider Trans-3.85%Inst Trans-0.50%
Short Float37.29%EarningsNov 05/a
Analyst Recom1.70Target Price36.13
Avg Volume296.03K52W Range20.84 - 37.13
Nov-06-19 02:07AMEdited Transcript of TRUP earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-05-19 07:35PMTrupanion (TRUP) Q3 Earnings and Revenues Beat Estimates Zacks
Nov-05-19 04:05PMTrupanion Reports Third Quarter 2019 Results GlobeNewswire
Oct-29-19 10:33AMAnalysts Estimate Trupanion (TRUP) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-27-19 02:04PMIs Trupanion Inc (TRUP) Going To Burn These Hedge Funds ? Insider Monkey
Oct-22-19 04:05PMTrupanion, Inc. Announces Third Quarter 2019 Earnings Release and Conference Call GlobeNewswire
Oct-15-19 03:37PMTrupanion Supports Australias Veterinary Professionals in their Mental Wellbeing through MightyVet GlobeNewswire
Oct-03-19 12:39PMBefore You Buy Trupanion, Inc. (NASDAQ:TRUP), Consider Its Volatility Simply Wall St.
Sep-26-19 06:00AMTrupanion Ranked #1 Medical Insurance Provider for Pets in Canada GlobeNewswire
Aug-29-19 06:58PMEdited Transcript of TRUP earnings conference call or presentation 30-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, and Puerto Rico. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians through third-party referrals and online member acquisition channels. The company was formerly known as Vetinsurance International, Inc. changed its name to Trupanion, Inc. in 2013. Trupanion, Inc. was founded in 2000 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RAWLINGS DARRYLPresident and CEOOct 25Sale22.454,00089,8001,450,499Oct 28 05:05 PM
RAWLINGS DARRYLPresident and CEOOct 10Sale21.434,00085,7061,454,499Oct 15 05:13 PM
DOAK MICHAELDirectorSep 30Option Exercise0.0078204,997Oct 02 05:37 PM
Ferracone Robin ADirectorSep 30Option Exercise0.0088604,911Oct 02 05:41 PM
DAVIDSON JACQUELINE LDirectorSep 30Option Exercise0.0092104,238Oct 02 05:46 PM
CompanyAquestive Therapeutics, Inc.
Market Cap99.49MEPS (ttm)-2.61
P/E-EPS this Y-535.20%
Forward P/E-EPS next Y21.70%
PEG-EPS past 5Y-65.70%
P/S1.85EPS next 5Y-
P/B-EPS Q/Q56.90%
Dividend-Sales Q/Q-20.10%
Insider Own8.90%Inst Own66.70%
Insider Trans-Inst Trans0.20%
Short Float1.91%EarningsNov 06/b
Analyst Recom1.80Target Price18.00
Avg Volume111.16K52W Range2.95 - 18.49
Nov-05-19 06:35PMAquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates Zacks
Nov-05-19 04:50PMAquestive Therapeutics Reports Third Quarter 2019 Financial Results and Raises 2019 Guidance GlobeNewswire
Oct-30-19 10:33AMAnalysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-18-19 10:43AMHave Insiders Been Buying Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares This Year? Simply Wall St.
Oct-16-19 07:06AMThe Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch Benzinga
Oct-15-19 05:41PMAquestive Therapeutics Reaffirms Full Year 2019 Revenue Guidance and Will Announce Third Quarter 2019 Financial Results and Recent Business Highlights on November 6, 2019 GlobeNewswire
Sep-30-19 07:00AMAquestive Therapeutics Announces Successful Completion of Phase 1 Trial for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) GlobeNewswire
Sep-03-19 03:25PMMarket Sentiment Around Loss-Making Aquestive Therapeutics, Inc. (NASDAQ:AQST) Simply Wall St.
Aug-30-19 06:00AMThere's Value In These 2 Small Beaten Down Biotech Stocks
Aug-26-19 08:30AMAquestive Therapeutics to Attend Two Upcoming Investor Conferences GlobeNewswire
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.
TickerAYR [NYSE]
CompanyAircastle Limited
IndustryRental & Leasing Services
Market Cap2.05BEPS (ttm)2.69
P/E10.27EPS this Y72.50%
Forward P/E10.46EPS next Y19.97%
PEG-EPS past 5Y51.20%
P/S2.29EPS next 5Y-0.27%
P/B1.02EPS Q/Q-70.20%
Dividend4.35%Sales Q/Q-41.50%
Insider Own30.85%Inst Own60.30%
Insider Trans-0.04%Inst Trans0.14%
Short Float1.78%EarningsNov 06/b
Analyst Recom3.10Target Price23.30
Avg Volume269.04K52W Range15.75 - 27.74
Nov-06-19 09:25AMAircastle Announces Fourth Quarter 2019 Quarterly Dividend PR Newswire
Nov-06-19 06:48AMUPDATE 2-Aircraft lessor Aircastle to be bought in $2.4 bln deal Reuters
Nov-06-19 06:19AMCORRECTED-Aircraft lessor Aircastle to be acquired in a $2.4 bln deal Reuters
Nov-06-19 06:00AMAircastle Limited Enters into Merger Agreement with Affiliates of Marubeni and Mizuho Leasing PR Newswire
Nov-05-19 05:43PMAirline busts create weakness for leased Boeing 777, Airbus A330 jets American City Business Journals
Oct-30-19 10:33AMAircastle (AYR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Oct-26-19 01:22PMDid Hedge Funds Drop The Ball On Aircastle Limited (AYR) ? Insider Monkey
Oct-24-19 07:38AMAircastle stock jumps premarket after company says it may sell itself MarketWatch
Oct-24-19 07:16AMAircastle Announces Review of Strategic Alternatives PR Newswire
Oct-22-19 04:15PMAircastle to Announce Third Quarter 2019 Earnings on November 6, 2019 PR Newswire
Aircastle Limited, through its subsidiaries, leases, finances, sells, and manages commercial flight equipment to airlines worldwide. As of December 31, 2018, its aircraft portfolio comprised 261 aircraft leased to 81 lessees located in 44 countries. Aircastle Limited was founded in 2004 and is based in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MERRIMAN RONALDDirectorMay 29Sale20.0610,000200,62028,921May 29 04:23 PM
Kriedberg MichaelChief Commercial OfficerMar 31Option Exercise0.0021,0430202,011Apr 02 04:17 PM
Beers Christopher L.Chief Legal OfficerFeb 26Sale20.7215,000310,72579,582Feb 27 05:03 PM
Kriedberg MichaelChief Commercial OfficerFeb 25Sale20.4535,000715,750180,968Feb 26 04:21 PM
TickerODP [NASD]
CompanyOffice Depot, Inc.
IndustrySpecialty Retail, Other
Market Cap1.21BEPS (ttm)0.05
P/E42.94EPS this Y20.40%
Forward P/E6.13EPS next Y0.00%
PEG3.87EPS past 5Y21.10%
P/S0.11EPS next 5Y11.10%
P/B0.57EPS Q/Q-230.70%
Dividend4.57%Sales Q/Q-1.50%
Insider Own0.30%Inst Own95.20%
Insider Trans0.00%Inst Trans-1.12%
Short Float4.72%EarningsNov 06/b
Analyst Recom3.40Target Price1.91
Avg Volume6.37M52W Range1.23 - 3.82
Nov-06-19 08:23AMOffice Depot's stock surges after profit beat, review of holding company reorganization announced MarketWatch
Nov-06-19 08:05AMOffice Depot (ODP) Q3 Earnings Surpass Estimates Zacks
Nov-06-19 06:50AMOffice Depot, Inc. Announces Review of Potential Holding Company Reorganization Business Wire
Nov-06-19 06:50AMOffice Depot Increases and Extends Existing Stock Repurchase Program and Declares Quarterly Cash Dividend of $0.025 Per Share Business Wire
Nov-06-19 06:50AMOffice Depot Announces Third Quarter 2019 Results Business Wire
Nov-05-19 12:00PMCompuCom Partners with Intel on Remote Endpoint Management Business Wire
Nov-04-19 08:45AMFactors to Know Ahead of Office Depot's (ODP) Q3 Earnings Zacks
Nov-04-19 08:05AMOffice Depot Provides Solutions to Help Small Businesses Unleash Their Full Potential This Holiday Season and Beyond Business Wire
Oct-30-19 05:45PMOffice Depot (ODP) Flat As Market Gains: What You Should Know Zacks
Oct-30-19 10:33AMOffice Depot (ODP) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Office Depot, Inc. provides business services and supplies, products, and technology solutions. The company operates in three divisions: Business Solutions, Retail, and CompuCom. The Business Solutions division offers office supply products and services through sales forces, catalogs, and telesales, as well as through Internet Websites in the United States, Puerto Rico, U.S. Virgin Islands, and Canada. The Retail division operates a chain of retail stores, which offer office supplies; technology products and solutions; business machines and related supplies; print, cleaning, breakroom, and facilities products; and furniture in the United States, Puerto Rico, and the U.S. Virgin Islands. Its stores also provide printing, reproduction, mailing, and shipping services. As of April 4, 2019, this division operated 1,350 office supply stores. The CompuCom division sells information technology (IT) outsourcing services and products in the United States, Canada, and Costa Rica. It offers a range of solutions, including end user computing support, managed IT services, data center monitoring and management, service desk, network infrastructure, IT workforce solutions, mobile device management, and cloud services. The company offers its products under various labels, including Office Depot, OfficeMax, Foray, Ativa, TUL, Realspace, WorkPro, Brenton Studio, Highmark, and Grand & Toy. Office Depot, Inc. was founded in 1986 and is headquartered in Boca Raton, Florida.
1 2 3 4 5 6 ... 10 11 next